This is a video blog from the MMV Peru team following the launch of the PAVE Peru feasibility study in March 2023. The study is sponsored by MMV and will examine the feasibility, acceptability, and cost implications of providing primaquine or tafenoquine after G6PD testing in real-world settings. The study is led by Universidad Peruana Cayetano Heredia (UPCH).